Linerixibat not checked

GSK · GSK2330672

FollowEvery change as it happens, and a Monday email
Next date
Phase 3 trial completes
Trials
1 active
3 in total · 1 in the EU
Targets
 

What this is

How it works
Ileal Bile Acid Transporter Inhibitor FDA class
Tested for
Pruritus
Main trialPhase 3
“This study evaluates the long-term safety and tolerability of linerixibat in Japanese adults with cholestatic pruritus in primary biliary cholangitis (PBC) who previously participated in the linerixibat long-term safety and efficacy study, LLSAT (NCT04167358). Participants will continue receiving linerixibat while researchers monitor adverse events and other safety measures to better understand the long-term safety of treatment and provide continued access to therapy.”In the company’s words, NCT07860710 on ClinicalTrials.gov
Other names
GSK2330672

Other drugs for Pruritus

All 16 drugs for Pruritus

Coming up1

Changes1

Last 90 days

Trials3

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting 23 Oct 2028 J-LINX: Japan LINerixibat eXtension Study
Phase 3Completed 30 Sep 2026 Linerixibat Long-term Safety, and Tolerability Study
Phase 2Completed 15 Apr 2020 Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Linerixibat

Following is part of Solo: you see every change to Linerixibat the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in